Harnessing the full potential of BH3 mimetics to treat blood cancers [ 2019 - ]

Research Grant

Researchers: Prof David Huang (Principal investigator)

Brief description I utilise knowledge gained from basic research to improve healthcare of patients. By exploiting our knowledge of how cell survival is controlled, I led the development of a new anti-cancer drug called venetoclax, now used for chronic lymphocytic leukaemia. I will undertake studies to ascertain how it can be best used in patients with other blood cancers, and begin to develop other similar drugs. My future research seeks to markedly improve treatment for Australian patients with blood cancers.

Funding Amount $785,385.00

Funding Scheme Research Fellowships

Notes Research Fellowship